Fig. 3.
uEGFR mutations confer a poor prognosis on first-generation EGFR-TKI treatment. a. Kaplan-Meier estimates of progression-free survival (PFS) in NSCLC patients with cEGFR or uEGFR mutations who had received first-generation EGFR-TKI treatment (N = 50). b. Kaplan-Meier estimates of overall survival (OS) using the external validation cohort patients (N = 156).